Abstract
Enflurane (Ethrane; Abbott Laboratories Ltd), a new inhalation anaesthetic, was used on 30 clinical cases. A surgical plane of anaesthesia was quickly obtained and recovery was rapid. Respiratory depression occurred with a reduction in rate which was more marked in deeper planes of anaesthesia. Hypotension was not severe and was more marked in deeper plans of anaesthesia. Clinically the agent did not appear to be a good analgesic. No signs of spontaneous muscle activity were seen, possibly due to premedication with acepromazine.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
